Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 17:10 ET | Source: Spherix Global Insights

Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma

EXTON, PA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and...
November 19, 2025 15:19 ET | Source: Spherix Global Insights

First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights

EXTON, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the...
November 19, 2025 13:13 ET | Source: Spherix Global Insights

Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements

Exton, PA, Nov. 19, 2025 (GLOBE NEWSWIRE) -- New data from Spherix Global Insights reveal that the U.S. market for paroxysmal nocturnal hemoglobinuria (PNH) is entering a new phase of dynamism,...
November 13, 2025 17:32 ET | Source: Spherix Global Insights

UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth

Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global...
November 12, 2025 09:25 ET | Source: Spherix Global Insights

Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease

Exton, PA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye...
November 06, 2025 10:24 ET | Source: Spherix Global Insights

Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years

EXTON, PA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the treatment landscape for systemic sclerosis...
November 03, 2025 11:57 ET | Source: Spherix Global Insights

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S....
October 31, 2025 10:37 ET | Source: Spherix Global Insights

Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications

EXTON, PA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth...
October 29, 2025 09:44 ET | Source: Spherix Global Insights

Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders

EXTON, PA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a...
October 28, 2025 09:24 ET | Source: Spherix Global Insights

Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights

EXTON, PA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of...